• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Pipeline needs are key to Biogen’s restructuring

Pipeline needs are key to Biogen’s restructuring

October 27, 2015
CenterWatch Staff

The need to revamp its drug pipeline by eliminating several research programs was a key factor behind Biogen’s recent decision to reduce its 8,000-person workforce by 11%, which will result in the loss of 880 jobs worldwide.

The Cambridge, Mass.-based biotech giant announced the layoffs, which include 400 positions out of about 3,300 in Massachusetts, on Oct. 21 as part of a corporate restructuring.

“The decision to reduce the company’s workforce was extremely difficult, but we believe these actions are necessary to fulfill our mission of bringing important new medicines to patients,” CEO George Scangos said in a prepared statement.

According to the company’s statement, Biogen is expected to save $250 million a year as a result of the changes.

The company announced the job cuts as it buoyed its profit outlook and reported a 12.7% jump in third-quarter earnings to nearly $966 million, or $4.15 a share. Shares closed up almost 4 percent Oct. 21 to $276.34.

The stock, which traded as high as $480.18 in March, has plunged more than 15 percent this year, according to published reports. Still, Biogen’s market value of more than $60 billion remains the highest for any Massachusetts company, and the company is the world’s largest maker of multiple sclerosis (MS) drugs.

Part of Biogen’s plan includes revitalizing sales of Tecfidera, which is a key revenue driver and enjoyed a 19% sales increase in the last quarter. The company plans to use the savings from the job cuts to support sales and marketing of Tecfidera, which has been approved to treat relapsing forms of MS.

Biogen also has indicated that a late-stage trial of Tysabri, which treats secondary progressive MS, did not meet key goals.

    Upcoming Events

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing